106 related articles for article (PubMed ID: 19604090)
1. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
Kong SY; Lim HS; Nam BH; Kook MC; Kim YW; Ryu KW; Lee JH; Choi IJ; Lee JS; Park YI; Kim NK; Park SR
Pharmacogenomics; 2009 Jul; 10(7):1147-55. PubMed ID: 19604090
[TBL] [Abstract][Full Text] [Related]
2. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
3. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
[TBL] [Abstract][Full Text] [Related]
5. A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Choi YH; Kim TW; Kim KP; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Ryoo BY; Kim HS; Shin JG; Kang YK
Oncology; 2012; 82(5):290-7. PubMed ID: 22555197
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
Kim KP; Jang G; Hong YS; Lim HS; Bae KS; Kim HS; Lee SS; Shin JG; Lee JL; Ryu MH; Chang HM; Kang YK; Kim TW
Br J Cancer; 2011 Feb; 104(4):605-12. PubMed ID: 21326246
[TBL] [Abstract][Full Text] [Related]
7. [The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].
Hu FK; Shen J; Gao SW
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1915-1918. PubMed ID: 29996281
[No Abstract] [Full Text] [Related]
8. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
[TBL] [Abstract][Full Text] [Related]
10. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
12. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
[TBL] [Abstract][Full Text] [Related]
13. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
14. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Ishii Y; Suzuki S; Takahashi Y; Takayama T; Asai S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):333-43. PubMed ID: 19921195
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
